Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) have received an average rating of “Moderate Buy” from the twenty-three ratings firms that are presently covering the stock, MarketBeat reports. Four investment analysts have rated the stock with a hold recommendation, eighteen have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $122.61.

Several analysts recently commented on the stock. Morgan Stanley cut their price objective on shares of Sarepta Therapeutics from $182.00 to $113.00 and set an “overweight” rating on the stock in a research report on Wednesday, May 7th. JPMorgan Chase & Co. cut their price objective on shares of Sarepta Therapeutics from $169.00 to $84.00 and set an “overweight” rating on the stock in a research report on Tuesday, May 20th. Royal Bank of Canada cut their price objective on shares of Sarepta Therapeutics from $87.00 to $58.00 and set a “sector perform” rating on the stock in a research report on Wednesday, May 7th. Piper Sandler cut their price objective on shares of Sarepta Therapeutics from $110.00 to $70.00 and set an “overweight” rating on the stock in a research report on Wednesday, May 7th. Finally, Cantor Fitzgerald dropped their price target on shares of Sarepta Therapeutics from $163.00 to $81.00 and set an “overweight” rating on the stock in a report on Wednesday, May 7th.

Insider Transactions at Sarepta Therapeutics

In other news, Director Claude Nicaise sold 2,491 shares of the stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $99.64, for a total value of $248,203.24. Following the transaction, the director now owns 27,812 shares in the company, valued at $2,771,187.68. This represents a 8.22% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Company insiders own 7.70% of the company’s stock.

Institutional Investors Weigh In On Sarepta Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Nisa Investment Advisors LLC lifted its holdings in Sarepta Therapeutics by 23.1% during the fourth quarter. Nisa Investment Advisors LLC now owns 1,317 shares of the biotechnology company’s stock valued at $160,000 after purchasing an additional 247 shares in the last quarter. Fifth Third Bancorp lifted its holdings in Sarepta Therapeutics by 219.7% during the fourth quarter. Fifth Third Bancorp now owns 1,832 shares of the biotechnology company’s stock valued at $223,000 after purchasing an additional 1,259 shares in the last quarter. Blue Trust Inc. lifted its holdings in Sarepta Therapeutics by 56.9% during the fourth quarter. Blue Trust Inc. now owns 891 shares of the biotechnology company’s stock valued at $111,000 after purchasing an additional 323 shares in the last quarter. Swedbank AB purchased a new position in Sarepta Therapeutics during the fourth quarter valued at approximately $16,706,000. Finally, China Universal Asset Management Co. Ltd. lifted its holdings in Sarepta Therapeutics by 10.4% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 20,254 shares of the biotechnology company’s stock valued at $2,463,000 after purchasing an additional 1,912 shares in the last quarter. Institutional investors own 86.68% of the company’s stock.

Sarepta Therapeutics Stock Performance

Shares of SRPT stock opened at $43.01 on Friday. Sarepta Therapeutics has a one year low of $34.10 and a one year high of $173.25. The company’s 50-day moving average is $47.99 and its 200 day moving average is $89.44. The company has a market capitalization of $4.23 billion, a price-to-earnings ratio of 34.41 and a beta of 0.61. The company has a debt-to-equity ratio of 0.93, a quick ratio of 3.03 and a current ratio of 3.84.

Sarepta Therapeutics (NASDAQ:SRPT) last announced its quarterly earnings data on Tuesday, May 6th. The biotechnology company reported ($3.42) EPS for the quarter, missing the consensus estimate of $2.20 by ($5.62). Sarepta Therapeutics had a net margin of 7.43% and a return on equity of 11.00%. The firm had revenue of $744.86 million for the quarter, compared to analysts’ expectations of $685.75 million. During the same period last year, the company posted $0.73 earnings per share. The business’s revenue for the quarter was up 80.2% compared to the same quarter last year. Sell-side analysts expect that Sarepta Therapeutics will post 2.67 EPS for the current fiscal year.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.